(secondQuint)A Study Of PF-06647263 In Patients With Advanced Solid Tumors.

 The clinical study will include 2 parts.

 Part 1 will estimate the MTD in dose escalation cohorts in patients with advanced solid tumors for whom no standard therapy is available in order to establish the RP2D.

 Part 2 will include patients with previously treated metastatic triple negative breast cancer (TNBC).

.

 A Study Of PF-06647263 In Patients With Advanced Solid Tumors@highlight

To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

